The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Parkinson's disease: Autoimmunity and neuroinflammation
Open accessAbstract
Parkinson's disease is a neurodegenerative disease that causes the death of dopaminergic neurons in the substantia nigra. The resulting dopamine deficiency in the basal ganglia leads to a movement disorder that is characterized by classical parkinsonian motor symptoms. Parkinson's disease is recognized as the most common neurodegenerative disorder after Alzheimer's disease. PD ethiopathogenesis remains to be elucidated and has been connected to genetic, environmental and immunologic conditions. The past decade has provided evidence for a significant role of the immune system in PD pathogenesis, either through inflammation or an autoimmune response. Several autoantibodies directed at antigens associated with PD pathogenesis have been identified in PD patients. This immune activation may be the cause of, rather than a response to, the observed neuronal loss. Parkinsonian motor symptoms include bradykinesia, muscular rigidity and resting tremor. The non-motor features include olfactory dysfunction, cognitive impairment, psychiatric symptoms and autonomic dysfunction. Microscopically, the specific degeneration of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies, which are brain deposits containing a substantial amount of α-synuclein, have been recognized. The progression of Parkinson's disease is characterized by a worsening of motor features; however, as the disease progresses, there is an emergence of complications related to long-term symptomatic treatment. The available therapies for Parkinson's disease only treat the symptoms of the disease. A major goal of Parkinson's disease research is the development of disease-modifying drugs that slow or stop the neurodegenerative process. Drugs that enhance the intracerebral dopamine concentrations or stimulate dopamine receptors remain the mainstay treatment for motor symptoms. Immunomodulatory therapeutic strategies aiming to attenuate PD neurodegeneration have become an attractive option and warrant further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · cited 1×
“These activators include fibrates and rosiglitazone (PPAR) [62,63], metformin [64], pyrroloquinoline quinone [65], 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) (AMPK) [66] and resveratrol (Sirt1) [67].”
BackgroundThe relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,246
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity
Van Den Eeden, S. K. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,747
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Research works printed but not linked: 5
- Manyam, 1999, Traditional and complementary therapies in Parkinson's disease, Adv Neurol, 80, 565
- Zhang, 2006, Early descriptions of Parkinson's disease in ancient China, Arch Neurol, 63, 782, 10.1001/archneur.63.5.782 · doi:10.1001/archneur.63.5.782
- Møller, 1989, Parkinson's disease and autoimmunity, Acta Neurol Scand, 79, 173, 10.1111/j.1600-0404.1989.tb03733.x · doi:10.1111/j.1600-0404.1989.tb03733.x
- Myers, 1976, Evidence for a dopamine receptor antibody, Biochem Biophys Res Commun, 72, 1311, 10.1016/S0006-291X(76)80158-1 · doi:10.1016/s0006-291x(76)80158-1
- Farooqui, 1991, Antibodies against synthetic peptides predicted from the nucleotide sequence of D2 receptor recognize native dopamine receptor protein in rat striatum, J Neurochem, 57, 1363, 10.1111/j.1471-4159.1991.tb08302.x · doi:10.1111/j.1471-4159.1991.tb08302.x
Cited by
The genetics of Parkinson disease
Deng, H., Wang, P., & Jankovic, J. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2017.12.007 · Cited by 530
Pyroptosis in health and disease: mechanisms, regulation and clinical perspective
Liu, Y., Pan, R., Ouyang, Y., Gu, W., Xiao, T., Yang, H., Tang, L., Wang, H., Xiang, B., & Chen, P. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01958-2 · Cited by 337
Regulation of Ketone Body Metabolism and the Role of PPARα
Grabacka, M., Pierzchalska, M., Dean, M., & Reiss, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122093 · Cited by 305
Biomarker of Neuroinflammation in Parkinson’s Disease
Liu, T.-W., Chen, C.-M., & Chang, K.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084148 · Cited by 259
Cheng, J., Liao, Y., Dong, Y., Hu, H., Yang, N., Kong, X., Li, S., Li, X., Guo, J., Qin, L., et al. (2020) · Autophagy · doi:10.1080/15548627.2020.1719723 · Cited by 233
Chiurchiù, V., van der Stelt, M., Centonze, D., & Maccarrone, M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.007 · Cited by 140
“An important role of the immune system in the pathogenesis of PD is recent and it seems to involve either inflammation or autoimmunity, due to the identification of several autoantibodies directed towards PD-associated antigens (De Virgilio et al., 2016).”
Ruan, Z., Zhang, D., Huang, R., Sun, W., Hou, L., Zhao, J., & Wang, Q. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052793 · Cited by 82
Cronin, A., & Grealy, M. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.10.018 · Cited by 68
Gonzalez-Riano, C., Saiz, J., Barbas, C., Bergareche, A., Huerta, J. M., Ardanaz, E., Konjevod, M., Mondragon, E., Erro, M. E., Chirlaque, M. D., et al. (2021) · npj Parkinson's Disease · doi:10.1038/s41531-021-00216-4 · Cited by 49
Yan, T., Mao, Q., Zhang, X., Wu, B., Bi, K., He, B., & Jia, Y. (2021) · Food & Function · doi:10.1039/d0fo02836c · Cited by 41
Sun, L., Jiang, W.-W., Wang, Y., Yuan, Y.-S., Rong, Z., Wu, J., Fan, Y., Lu, M., & Zhang, K.-Z. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00676-w · Cited by 31
Heinzerling, K. G., Briones, M., Thames, A. D., Hinkin, C. H., Zhu, T., Wu, Y. N., & Shoptaw, S. J. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09883-w · Cited by 30
Safety of Plasma Infusions in Parkinson's Disease
Parker, J. E., Martinez, A., Deutsch, G. K., Prabhakar, V., Lising, M., Kapphahn, K. I., Anidi, C. M., Neuville, R., Coburn, M., Shah, N., et al. (2020) · Movement Disorders · doi:10.1002/mds.28198 · Cited by 23
RACF: A Multimodal Deep Learning Framework for Parkinson’s Disease Diagnosis Using SNP and MRI Data
Cao, J., & Long, X. (2025) · Applied Sciences · doi:10.3390/app15084513 · Cited by 22
Fenner, B. M., Fenner, M. E., Prowse, N., & Hayley, S. P. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30588 · Cited by 14
“…microglial activation (Cookson, 2015; Gillardon et al., 2012; K. S. Kim et al., 2018; Subramaniam & Federoff, 2017), leading to the production of inflammatory factors, ROS, and increased microglial phagocytic capacity (De Virgilio et al., 2016; González et al., 2015; Subramaniam & Federoff, 2017).”
Background
Metadata
- Authors
- De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M. I., Gallo, A., Conte, M., Rosato, C., Ciniglio Appiani, M., & de Vincentiis, M.
- Venue
- Autoimmunity Reviews
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 15
- Issue
- 10
- Pages
- 1005-1011
- ISSN
- 1568-9972 (ISSN-L)
- OpenAlex
- W2494229447
- Cited by
- 389
- References
- 61
- FWCI
- 20.17
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-12-01)
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.